Washington, DC, United States of America – August 29, 2011
08:31 AM (GMT -5:00) Eastern Time
Constellation Research Inc, a next generation research analyst and advisory firm helping clients navigate emerging and disruptive technologies, announced today the addition of Nigel Cameron to the Board of Advisors. Cameron currently serves as the President of The Center For Policy On Emerging Technologies (C-PET). C-PET is a Washington, D.C. based think tank that explores the impact of transformative emerging technologies and anticipates their implications for public policy.
Constellation Research’s Board of Advisors play a key role in shaping the research agenda and providing advice and guidance to its members. Board members bring significant industry experience, represent the leaders in their field, and serve in 6 to 12 month terms. These esteemed individuals:
- Guide research direction
- Advise on business strategy
- Maintain an outside-in perspective
- Deliver mentorship from seasoned professionals
- Garner input from clients and prospects
- Grow the constellation of experts
- Identify new talent
- Maintain and exude the Constellation values in public
Advisory Board members do not have a commercial relationship with Constellation nor are they represented by Constellation. Board members do not have fiduciary responsibility.
Nigel M. de S. Cameron is an inter-disciplinary scholar, facilitator and communicator who has worked on both sides of the Atlantic and initiated projects at the interface of science, technology, values, business, and policy. A graduate of Cambridge and Edinburgh Universities and the Edinburgh Business School, he is currently President and CEO of the Center for Policy on Emerging Technologies (C-PET), Washington’s first nonpartisan think tank focused on the long-term policy impacts of emerging technologies. Before founding C-PET, he served as a Research Professor and Associate Dean of the College of Law of the Illinois Institute of Technology (IIT), where he also directed an institute on biotechnology policy and established the first U.S. university-based center on nanotechnology and its social implications, chairing its annual conferences for policymakers in Washington, DC, and initiating the Chicago Nano Forum for city business, law and technology leaders. He also led a study of the multi-sectoral implications of diabetes for IIT’s Center for Diabetes Research and Policy, and convened a national conference on diabetes policy with participation from such actors as PAHO, HHS, and the State of Illinois.
He has written widely on the policy and ethics implications of emerging technologies, both at an academic level and in popular media. He has appeared on such network television programs as ABC Nightline and PBS Frontline, and been published in many contexts including the San Francisco Chronicle, the Chicago Tribune, the London Guardian – as well as law reviews, Nature Biotechnology, and Nanotechnology Law and Business. In 1983 he founded the journal Ethics and Medicine, and his books include The New Medicine: Life and Death after Hippocrates and Nanoscale: Issues and Perspectives for the Nano Century. In addition to essays on innovation and technology policy, he currently writes a regular column for the U.S. Chamber of Commerce on the corporate social responsibility impacts of new technologies.
Among recent commitments, he has been a featured speaker at the Aspen Ideas Festival and was invited to moderate a panel on radical life extension at the Aspen Global Health Forum. At a recent World Healthcare Innovation and Technology Congress, he led an interactive plenary session on the likely business impacts of developments in nanotechnology, and has also addressed developments in personalized medicine and co-presented with a member of Congress on the politics of enhanced human intelligence. He has several times been invited to be executive-in-residence at the UBS executive development center at Wolfsberg, and been a featured presenter at the STARS emerging business leaders symposium (Switzerland). He chaired the track on governance at a recent Beijing conference on nanotechnology; presented on life extension and how to think about the future at finance leader AMP’s innovation festival Amplify in where he was also a panelist on the future of mobile technology (Sydney, Australia); and has chaired recent conferences in London on personalized medicine (at the Biochemical Society) and emerging technology policy (House of Lords). Upcoming commitments include moderating a high-level panel on innovative technology responses at the global Planet under Pressure conference (2012).
Dr. Cameron has also been significantly engaged in both domestic and global policy issues. He was an invited non-federal participant in the U.S. Government inter-agency strategic planning process Project Horizon. He was an invited participant in Sandia National Laboratory’s consultation on the implications of artificially enhanced human intelligence. He co-chaired a workshop hosted by the White House Office of Science and Technology Policy to scope the policy and broader societal implications of nanotechnology. He has given invited testimony before committees of both U.S. House and Senate (Commerce, Appropriations, Foreign Affairs); the UK House of Commons; the European Parliament; and the European Commission’s advisory Group on Ethics in Science and New Technologies. He was an invited U.S. participant in the U.S./European Commission dialogue on Perspectives on the Future of Science and Technology. In 2007, he was the United States’ nominee to the UN Human Rights Council to be Special Rapporteur for the Right to Health. He has also represented the United States on delegations to the United Nations, and is currently a Commissioner and Chair of the Social and Human Sciences Committee of the United States National Commission for UNESCO. A native of the United Kingdom, he is a naturalized United States citizen.
“I’m deeply impressed by Constellation’s cutting-edge research agenda. Constellation’s focus on disruptive technology offers a perfect complement to the work we’re doing at C-PET. It’s a privilege to be invited, and there’s tremendous opportunity to provide input into the research agenda and share insights as – together – we “ask Tomorrow’s Questions,” stated Nigel Cameron
“Nigel’s a pioneer in bringing a non-partisan view on technology policy. I’m counting on his insights to help us shape our research agenda. If we can bring the right alignment between our research and future technology policy, we can truly harness the impact of disruptive technologies in a systemic manner”, said R “Ray” Wang, Principal Analyst and CEO.
C-PET Website: http://c-pet.org/
Geo: Washington, D.C.; Chicago, Illinois, USA
C-PET is a Knowledge Network Asking Tomorrow’s Questions
The United States has long dominated the global technology agenda and served as the spearhead to innovation of all kinds. Yet on almost all indicators, this is no longer the most competitive or innovation-friendly economy. And perhaps the single most troubling feature of Washington, DC is the absence of serious engagement with long-term technology issues from the top of the federal policy agenda – and, alike, from the efforts of think tanks and other groups to shape that agenda. Nowhere is the short-term nature of political vision and decision-making both inside and outside government more evident than here.
C-PET is being developed to address this complex situation. Most think tanks take clear positions on issues of controversy, or have a clear ideological/partisan orientation, or some combination of the two. We put as much effort into how we think as what we think. We are a knowledge network, drawing together thinkers with wide interests and deep expertise from across the silos within which so much thinking still takes place. And while most “think tanks” focus on answers, we ask questions; indeed, our chief focus is on clarifying what the big questions are – “tomorrow’s questions.” It is as we identify, clarify and prioritize the “big questions” raised in future perspective (our rule-of-thumb is a 10-year time horizon) that we cultivate a context within which solutions can be developed. By determining to be nonpartisan and non-ideological we are not stating that we have no view. We are rather affirming our commitment to the long term, to the framing of questions as the context for answers, and to the participation of thinkers of diverse views and expertise in shaping the conversation.
Our Board of Directors includes lead biotech investor Steve Burrill (Burrill Life Sciences); Marty Apple, president of the Council of Scientific Society Presidents; internet guru Mike Nelson (Georgetown and Leading Edge Forum), and John Palafoutas, Executive Director of the Intel-led Task Force on American Innovation.
About Constellation Research, Inc
. Constellation Research is a leading research analyst and advisory firm guiding organizations and their leaders through the hype and buzz of the latest disruptive technologies. Constellation takes a holistic approach touching board members, and marketing, technology, operations, human resource, and finance executives.
The firm’s analysts deliver pragmatic, creative, and disruptive research focused on business value, profitability, and market differentiation. Research analysts bring real world experience, independence, and objectivity to our clients. Most analysts bring over 2 decades of hands-on experience in working with senior leaders in enterprise organizations.
Constellation serves the needs of buyers and end users who seek insight, guidance, and advice in dealing with a dizzying array of disruptive business models and technologies. The firm provides the bridge between legacy optimization and future innovation. Constellation also advises sellers from both the buyer’s point of view and how to deliver value to their customers.
Constellation builds partnerships with its clients. The client and their organization’s success is Constellation’s only mission.
Contact the Media and Influencers relations team at press@ConstellationRG.com for interviews with analysts.
For more information on how to engage with Constellation Research, Inc. contact:
David Stanley, Vice President of Business Development and Sales
• Email: David@ConstellationRG.com
• Office: 719.357.7826
• Twitter: @kiwigate
Kieran Barr, Senior Director of Business Development and Sales
• Email: Kieran@ConstellationRG.com
• Office: 206.409.5009
• Twitter: @kierobar